<DOC>
	<DOCNO>NCT00312221</DOCNO>
	<brief_summary>The objective study demonstrate effectiveness tolerability buprenorphine transdermal system ( 20 mg ) comparison buprenorphine transdermal system ( 5 mg ) oxycodone immediate release subject moderate severe osteoarthritis pain currently treat oral opioids . The double-blind treatment intervention duration 12 week time supplemental analgesic medication ( acetaminophen , ibuprofen , immediate release oxycodone ) provide subject addition study drug .</brief_summary>
	<brief_title>Safety Efficacy Buprenorphine Transdermal System ( BTDS ) Subjects With Moderate Severe Osteoarthritis Pain</brief_title>
	<detailed_description>Buprenorphine synthetic opioid analgesic twenty-five year international clinical experience indicate safe effective variety therapeutic situation relief moderate severe pain .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Osteoarthritis hip , knee , spine 1 year longer , confirm radiographic evidence within last 2 year . Good pain control stable dose opioid analgesic osteoarthritis . Not currently take tolerate opioids . Taking 80 mg per day oral morphine sulfate equivalent within 30 day enrollment . Requiring frequent analgesic therapy chronic condition ( ) , addition osteoarthritis . Other protocolspecific exclusion/inclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Osteoarthritis , opioid , transdermal</keyword>
</DOC>